Publication Name	World Journal of Gastroenterology
Manuscript ID	6824
Country	South Korea

Received	2013-10-29 12:15
Peer-Review Started	2013-10-29 19:05
To Make the First Decision	2013-11-21 19:03
Return for Revision	2013-11-22 10:32
Revised	2013-12-13 12:21
Second Decision	2014-01-15 20:17
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-01-15 20:31
Articles in Press	2014-05-23 11:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-13 14:03
Publish the Manuscript Online	2014-06-21 13:56

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response
Manuscript Source	Invited Manuscript
All Author List	Wonseok Kang and Jun Yong Park
Funding Agency and Grant Number	Funding Agency Grant Number Liver Cirrhosis Clinical Research Center Korea Healthcare Technology R and D project, Ministry of Health and Welfare, Republic of Korea HI10C2020
Corresponding Author	Jun Yong Park, MD, PhD, Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. drpjy@yuhs.ac
Key Words	Chronic hepatitis B; Antiviral therapy; Nucleos(t)ide analogue; Durability; Cessation
Core Tip	Introduction of nucleos(t)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome in patients with chronic hepatitis B (CHB). While attention has been drawn to whether antiviral treatment with NAs can be a finite therapy in patients with CHB, current guidelines for stopping NA therapy seems to be inadequate in terms of off-treatment durability in both hepatitis Be antigen (HBeAg)-positive and HBeAg-negative patients. In the present work, we discussed the validity of current stopping rules of NA therapy and addressed areas of uncertainty in deciding the best timing to stop NA treatment.
Publish Date	2014-06-21 13:56
Citation	Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212
URL	http://www.wjgnet.com/1007-9327/full/v20/i23/7207.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i23.7207

Full Article (PDF)	WJG-20-7207.pdf
Full Article (Word)	WJG-20-7207.doc
Manuscript File	6824-Review.docx
Answering Reviewers	6824-Answering Reviewers.pdf
Copyright License Agreement	6824-Copyright Assignment.pdf
Peer-review Report	6824-Peer review(s).pdf
Scientific Editor Work List	6824-Scientific editor work list.doc